2016 Fiscal Year Final Research Report
Development of adjuvants for CTL induction using high active form of lymphotactin/XCL1
| Project/Area Number |
26860775
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | ケモカイン / ワクチン / アジュバント / CTL |
|---|
| Outline of Final Research Achievements |
Recent studies have indicated that targeting antigens to XCR1, a chemokine receptor selectively expressed on cross-presenting dendritic cells using antigen fused to XCL1/Lymphotactin, an XCR1 ligand, represents an effective induction of CD8+ T cell response. In this study, we generate a high active form of XCL1 (XCL1-CC3) and investigate in vivo adjuvant efficacy. Wild-type XCL1 (XCL1-WT) have higher cell migration activity and calcium mobilization activity than XCL1-CC3. When intradermally injected with ovalbumin as a model antigen, both XCL1-WT and XCL1-CC3 induced potent CD8+ T cell responses and XCL1-CC3 showed more effective CD8+ T cell-mediated antitumor immunity than XCL1-WT. In addition, XCL1-CC3 enhanced an accumulation of CD103+XCR1+ cross-presenting dendritic cells rather than XCL1-WT. The present results indicate that XCL1-CC3 has potential to induce more efficient CD8+ T cells responses as CTL-inducing vaccine adjuvant than XCL1-WT.
|
| Free Research Field |
免疫学
|
